Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1658828 | 0.90 | KDM4E (0.71) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL6379762 | 0.89 | KDM4E (0.78) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL5358840 | 0.85 | ACHE (0.59) | — | |
| SCHEMBL15899217 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL17320354 | 0.84 | KDM4E (0.85) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL18093460 | 0.82 | ALDH1A1 (0.81) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL28396409 | 0.82 | ACHE (0.55) | — | |
| SCHEMBL4730776 | 0.81 | ALDH1A1 (0.70) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL6383092 | 0.81 | ALDH1A1 (0.70) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL4859012 | 0.81 | ACHE (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376387-B2 | Oxidisable pyridine derivatives, their preparation and use as anti-alzheimer agents | INSA INST NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2016-06-28 | — | — | US | disclosed |
| US-9376387-B2 | Oxidisable pyridine derivatives, their preparation and use as anti-alzheimer agents | INSA INST NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2016-06-28 | — | — | US | disclosed |
| US-9376387-B2 | Oxidisable pyridine derivatives, their preparation and use as anti-alzheimer agents | INSA INST NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2016-06-28 | — | — | US | disclosed |
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2015-12-10 | — | — | US | disclosed |
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2015-12-10 | — | — | US | disclosed |
| EP-2948429-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | INSA (Institut National des Sciences Appliquees) de Rouen (FR) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114742-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | INSA (INSTITUT NATIONAL DES SCIENCES APPLIQUÉES) DE ROUEN (FR) | 2014-07-31 | — | — | WO | disclosed |
| EP-2759536-A1 | Oxidisable pyridine derivatives, their preparation and use as anti-Alzheimer agents | INSA (Institut National des Sciences Appliquees) de Rouen (FR) | 2014-07-30 | — | — | EP | disclosed |
| EP-2759536-A1 | Oxidisable pyridine derivatives, their preparation and use as anti-Alzheimer agents | INSA (Institut National des Sciences Appliquees) de Rouen (FR) | 2014-07-30 | — | — | EP | disclosed |
| JP-2004131465-A | PRODUCTION METHOD OF DONEPEZIL | CHEMAGIS LTD | 2004-04-30 | — | — | JP | disclosed |
| US-20040048893-A1 | Process for the preparation of donepezil | CHEMAGIS LTD (IL) | 2004-03-11 | — | — | US | disclosed |
| EP-1386607-A1 | Process for the preparation of Donepezil | CHEMAGIS LTD. (IL) | 2004-02-04 | — | — | EP | disclosed |
| US-6252081-B1 | REDUCING OF THE COORRESPONDING QUATERNARY AMMONIUM SALT | EISAI CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-1047674-A1 | PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036405-A1 | PROCESS FOR PRODUCTION OF DONEPEZIL DERIVATIVE | EISAI CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
| EP-0383318-B1 | Aralkylamine compounds | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-12-14 | — | — | EP | disclosed |
| US-5296482-A | (Benzocycloalkyl) alkylamines | ADIR ET COMPAGNIE (FR) | 1994-03-22 | — | — | US | disclosed |
| US-5180746-A | Cholinesterase Inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-01-19 | — | — | US | disclosed |
| EP-0383318-A2 | Aralkylamine compounds | Takeda Chemical Industries, Ltd. (JP) | 1990-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353493-A1 | OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS | CBR3, CBR1, CYB5R3 | KDM4E 2033/4885ALDH1A1 3811/4885KMT2A 3572/4885 |
| US-20040048893-A1 | Process for the preparation of donepezil | ACHE, BCHE, CYP4Z1 | KDM4E 274/4885ALDH1A1 597/4885KMT2A 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.